title: DIAPREV-IT study of diabetes therapy Diamyd® receives further funding and will continue despite disappointing Phase III trial results.
mesh_terms: D000818:Animals; D001324:Autoantigens / Q000276:immunology*; D002648:Child; D017326:Clinical Trials, Phase III as Topic; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy* / Q000276:immunology; D018450:Disease Progression; D005060:Europe; D005378:Financial Support; D005968:Glutamate Decarboxylase / Q000276:immunology*; D006801:Humans; D016896:Treatment Outcome; D014611:Vaccination
chemical_list: D001324:Autoantigens; D005968:Glutamate Decarboxylase; C401141:glutamate decarboxylase 2